Levothyroxine: A black swan? [BE/BA News]

posted by DavidManteigas – Portugal, 2017-11-27 18:53 (1948 d 14:03 ago) – Posting: # 18014
Views: 7,298

There isn't any biological background that might explain this issue? Or problems during manufacturing? This is really awkward... the CI and point estimate are far more "perfect" than I am used to see. In fact, in full replicate studies, I've seen reference drugs "performing" poorly when compared with single administrations of themselves... Is the dose-toxicity so sensible for this drug that event the narrower limits does not apply in this case? Did a quick search and haven't find any study reporting the dose-response of this drug

Complete thread:

UA Flag
 Admin contact
22,557 posts in 4,724 threads, 1,608 registered users;
13 visitors (0 registered, 13 guests [including 7 identified bots]).
Forum time: 09:57 CEST (Europe/Vienna)

A scientist’s aim in a discussion with his colleagues
is not to persuade, but to clarify.    Leo Szilard

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz